Study on the efficacy and safety of Pamrevlumab in patients with idiopathic pulmonary fibrosis
Résumé de l'étude
The aim of this study is to investigate the efficacy and safety of Pamrevlumab compared to placebo (a substance that looks like the investigational drug but contains no active ingredient) as monotherapy in patients (Pat.) with idiopathic pulmonary fibrosis (IPF). Pat. who have previously been treated with already approved IPF therapies may participate in the study, provided the Pat. is not currently being treated with an approved IPF therapy. Approximately 340 Pat. will participate in this study. In Switzerland about 3 Pat. As the study investigates how well Pamrevlumab works, the Pat. will be divided into two different groups. The Pat. in one group will receive Pamrevlumab, the investigational drug. The Pat. in the other group will receive a placebo. Form of participation: If you choose to participate, the investigational drug will be administered to you via a needle directly into a vein (this procedure is called infusion). Overall, you will receive 17 infusions over a period of 48 weeks (W). After the visit (V) at W 48, you may choose to participate in the open-label extension. Number and effort of V and corresponding restrictions: If you participate in the study, you will start with a pre-screening phase. This lasts up to 6 W and includes several V. Each V can last between 3 and 5 hours. After the pre-screening phase, you will need to attend 17 V over a period of 48 W. Each V can last between 1 and 4 hours. 4 W after your last treatment with the investigational drug, a safety follow-up will take place and a follow-up phone call will occur at W 9. Various tests will be conducted as part of the study, including: measurement of vital parameters (blood pressure, pulse, and temperature), physical examination, electrocardiogram, blood tests, high-resolution computed tomography (HRCT), questionnaires.
(BASEC)
Intervention étudiée
- In the presence of idiopathic pulmonary fibrosis (IPF), the approved therapy for IPF will be administered according to the standard of care.
- The aim of this study is to investigate whether the new treatment (Pamrevlumab) is superior to placebo (a drug without active ingredient).
(BASEC)
Maladie en cours d'investigation
Idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis, IPF)
(BASEC)
- Diagnosis of IPF according to guidelines - IPF diagnosis within the last seven years - Interstitial lung fibrosis, defined by HRCT scan (BASEC)
Critères d'exclusion
- Previous treatment with Pamrevlumab. - Evidence of significant obstructive lung disease (narrowing of the airways). - Interstitial lung disease (disease of the interstitial space of the lung IDL) except for IPF. (BASEC)
Lieu de l’étude
Berne
(BASEC)
Sponsor
non disponible
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
PD Dr. Manuela Funke-Chambour.
+41 31 632 80 99
manuela.funke-chambour@clutterinsel.ch(BASEC)
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique de Berne
(BASEC)
Date d'approbation du comité d'éthique
30.05.2022
(BASEC)
Identifiant de l'essai ICTRP
NCT04419558 (ICTRP)
Titre officiel (approuvé par le comité d'éthique)
non disponible
Titre académique
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) (ICTRP)
Titre public
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ICTRP)
Maladie en cours d'investigation
Idiopathic Pulmonary Fibrosis (ICTRP)
Intervention étudiée
Drug: Pamrevlumab;Drug: Placebo (ICTRP)
Type d'essai
Interventional (ICTRP)
Plan de l'étude
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). (ICTRP)
Critères d'inclusion/exclusion
Gender: All
Maximum age: 85 Years
Minimum age: 40 Years
Key Inclusion Criteria:
1. Diagnosis of IPF as defined by American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/Latin American Thoracic Association
(ATS/ERS/JRS/ALAT) guidelines within the past 7 years prior to study participation.
2. High-resolution computed tomography (HRCT) scan at Screening, with =10% to <50%
parenchymal fibrosis (reticulation) and <25% honeycombing.
3. FVCpp value >45% and <95% at Screening and Day 1 (prior to randomization).
4. Diffusing capacity of the lungs for carbon monoxide (DLCO) percent predicted =25%
and =90%.
5. Not currently receiving treatment for IPF with an approved therapy for IPF (such as,
pirfenidone or nintedanib) for any reason, including prior intolerance or lack of
response to an approved IPF therapy, or choice to forego treatment with an approved
IPF therapy after a full discussion with the Investigator regarding risks/benefits
of such therapy.
Key Exclusion Criteria:
1. Previous exposure to pamrevlumab.
2. Evidence of significant obstructive lung disease, as evidenced by spirometry or
HRCT.
3. Female participants who are pregnant or nursing.
4. Smoking within 3 months of Screening and/or unwilling to avoid smoking throughout
the study.
5. Interstitial lung disease other than IPF.
6. Sustained improvement in the severity of IPF during the 12 months prior to
screening.
7. Other types of respiratory diseases that, in the opinion of the Investigator, would
impact the primary protocol endpoint or otherwise preclude participation in the
study, including diseases of the airways, lung parenchyma, pleural space,
mediastinum, diaphragm, or chest wall.
8. Certain medical conditions, that, in the opinion of the Investigator, would impact
the primary protocol endpoint or otherwise preclude participation in the study (such
as, myocardial infarction/stroke, severe chronic heart failure, pulmonary
hypertension, or cancers).
9. Acute IPF exacerbation during Screening or Randomization including hospitalization
due to acute IPF exacerbation within 4 weeks prior to or during screening.
10. Use of any investigational drugs or unapproved therapies, or participation in any
clinical trial with an investigational new drug within 30 days prior to screening.
Or use of approved IPF therapies (such as, pirfenidone or nintedanib) within 1 week
prior to screening.
11. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine
monoclonal antibodies, or to any component of the excipient. (ICTRP)
non disponible
Critères d'évaluation principaux et secondaires
DB Period: Change From Baseline in FVC at Week 48 (ICTRP)
DB Period: Time to Disease Progression;DB Period: Change From Baseline in Quantitative Lung Fibrosis (QLF) Volume at Week 48;DB Period: Time to First Occurrence of Any Component of the Clinical Composite Endpoint, Whichever Occurred First;DB Period: Time to First Acute IPF Exacerbation;DB Period: Time to All-Cause Mortality;DB Period: Time to First Respiratory Hospitalization (ICTRP)
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
Tracy Ganske;Research Center, tganske@fibrogen.com, (415) 978-1427; (ICTRP)
ID secondaires
FGCL-3019-095 (ICTRP)
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
https://clinicaltrials.gov/ct2/show/NCT04419558 (ICTRP)
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible